close

Fundraisings and IPOs

Date: 2017-03-15

Type of information: Subvention

Company: Autifony Therapeutics (UK)

Investors: Innovate UK (UK) the Dementia Discovery Fund (UK)

Amount: £1.7 million

Funding type: subvention

Planned used: Autifony Therapeutics will use this funding award for initiation of a research programme with a novel approach to the treatment of dementia. The company will use its expertise in the voltage-gated ion channel field to tackle a different subtype of potassium channel, which has been implicated in Alzheimer’s disease and potentially other dementias, through regulation of synapse function. Synaptic function is impaired early in the course of the disease and therefore novel drugs that target this previously unexplored ion channel could have potential not only to improve symptoms of AD, but to be disease modifying.  

Others: • On March 15, 2017, Autifony Therapeutics announced a new funding award of £895,000 from the Biomedical Catalyst for initiation of a research programme with a novel approach to the treatment of dementia. An investment of £400,000 from the Dementia Discovery Fund (“DDF”) will also be used to pursue this highly novel approach to dementia treatment.?

Therapeutic area: CNS diseases - Mental diseases

Is general: Yes